Linezolid-Associated Neurologic Adverse Events in Patients with Multidrug-Resistant Tuberculosis, France

Linezolid is one of the most effective drugs for treating multidrug-resistant tuberculosis (MDR TB), but adverse effects remain problematic. We evaluated 57 MDR TB patients who had received >1 dose of linezolid during 2011–2016. Overall, patients received 600 mg/day of linezolid for a median of 1...

詳細記述

保存先:
書誌詳細
出版年:Emerg Infect Dis
主要な著者: Jaspard, Marie, Butel, Nathalie, El Helali, Najoua, Marigot-Outtandy, Dhiba, Guillot, Helene, Peytavin, Gilles, Veziris, Nicolas, Bodaghi, Bahram, Flandre, Philippe, Petitjean, Gregoire, Caumes, Eric, Pourcher, Valerie
フォーマット: Artigo
言語:Inglês
出版事項: Centers for Disease Control and Prevention 2020
主題:
Research
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7392460/
https://ncbi.nlm.nih.gov/pubmed/32687026
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3201/eid2608.191499
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料